Table 2.
Overall survival (median and 3-year) by subgroups.
| n | Median (months) | 3-year (%) | p-value | |
|---|---|---|---|---|
| Age | ||||
| 18–59 | 261 | 25.9 | 35 | <0.001 |
| 60–69 | 349 | 24.7 | 33 | |
| 70–79 | 362 | 21.8 | 31 | |
| 80+ | 137 | 16.9 | 18 | |
| Gender | ||||
| Men | 355 | 20.6 | 27 | 0.15 |
| Women | 754 | 24.4 | 33 | |
| Histology | ||||
| Adeno | 1035 | 23.2 | 31 | 0.24 |
| Large NOS | 74 | 19.2 | 26 | |
| TKI | ||||
| Gefitinib | 213 | 19.7 | 26 | 0.29 |
| Erlotinib | 470 | 23.2 | 32 | |
| Afatinib | 161 | 23.3 | 34 | |
| Osimertinib | 265 | 22.8 | – | |
| WHO PS | ||||
| 0 | 406 | 26.8 | 34 | <0.001 |
| 1 | 329 | 23.2 | 32 | |
| 2+ | 135 | 13.1 | 16 | |
| Unknown | 239 | 21.2 | 32 | |
| TNM M | ||||
| 1A | 289 | 28.5 | 41 | <0.001 |
| 1B/C | 820 | 21.2 | 27 | |
| Period | ||||
| 2015–2017 | 468 | 21.0 | 29 | 0.10 |
| 2018–2020 | 641 | 24.1 | 32 | |
| Brain metastases | ||||
| Yes | 230 | 21.0 | 27 | 0.20 |
| No | 879 | 23.3 | 32 | |
| Number of metastatic organs | ||||
| 1 | 500 | 26.4 | 37 | <0.001 |
| 2 | 335 | 24.0 | 31 | |
| 3+ | 274 | 17.7 | 18 | |
| Mutation | ||||
| Del19 | 654 | 28.4 | 37 | <0.001 |
| L858R | 455 | 17.7 | 22 | |
| PD-L1 | ||||
| 0 | 322 | 27.6 | 37 | 0.07 |
| 1–49 | 182 | 21.8 | 25 | |
| 50+ | 128 | 20.8 | 32 | |
| Unknown | 477 | 21.2 | 29 |
TKI: tyrosine kinase inhibitor, WHO PS: World Health Organization performance score.